INVOLVEMENT OF RUNX1 IN DRUG RESISTANCE IN TNBC SUBTYPE.

SOFIA M SOSA; NATALIA FERNANDEZ; FACUNDO COUTO; ANA R RAIMONDI; NATALIA RUBINSTEIN

Buenos Aires

Congreso; Reunion Anual de la Sociedad de Biociencias 2021; 2021

SAIC

Triple negative breast cancer (TNBC) is associated with epithelial-mesenchymal transition (EMT) and an enrichment in cancer stem cell (CSC) population, which according to growing evidence, are involved in tumor chemoresistance. Our group has shown that RUNX1 could be involved in the aggressiveness of this breast cancer subtype. We reported that RUNX1 is able to promote cell migration and regulate tumor gene expression, such as the oncogene RSPO3 and the metastasis marker gene GJA1. ChIP assays done in our lab revealed that RUNX1 can regulate transcription factors involved in EMT. Moreover, RUNX1 protein expression in TNBC correlates with poor patient prognosis. Our aim was to evaluate RUNX1 relevance in drug treated human TNBC cell lines. Here we show that RUNX1, KLF4 (stemness marker) and GJA1 gene expression are significantly upregulated in doxorubicin-or paclitaxel-treated TNBC cell lines (all p values were at least